JP2020516293A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516293A5 JP2020516293A5 JP2019555915A JP2019555915A JP2020516293A5 JP 2020516293 A5 JP2020516293 A5 JP 2020516293A5 JP 2019555915 A JP2019555915 A JP 2019555915A JP 2019555915 A JP2019555915 A JP 2019555915A JP 2020516293 A5 JP2020516293 A5 JP 2020516293A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- optionally
- deletion
- nucleotides
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762484841P | 2017-04-12 | 2017-04-12 | |
| US62/484,841 | 2017-04-12 | ||
| PCT/US2018/027375 WO2018191545A1 (en) | 2017-04-12 | 2018-04-12 | Multiple transgene recombinant adenovirus |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020516293A JP2020516293A (ja) | 2020-06-11 |
| JP2020516293A5 true JP2020516293A5 (enExample) | 2021-05-27 |
| JP7301748B2 JP7301748B2 (ja) | 2023-07-03 |
Family
ID=63792941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019555915A Active JP7301748B2 (ja) | 2017-04-12 | 2018-04-12 | 複数トランスジーン組み換えアデノウイルス |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12036247B2 (enExample) |
| EP (1) | EP3610025A4 (enExample) |
| JP (1) | JP7301748B2 (enExample) |
| KR (1) | KR20200006058A (enExample) |
| CN (1) | CN110914440A (enExample) |
| EA (1) | EA201990822A1 (enExample) |
| WO (1) | WO2018191545A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| PL3198009T3 (pl) | 2014-09-24 | 2022-01-24 | Salk Institute For Biological Studies | Onkolityczne wirusy nowotworowe i sposoby zastosowania |
| JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| WO2018111767A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| JP7430395B2 (ja) | 2018-04-09 | 2024-02-13 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 複製特質が増強された腫瘍溶解性アデノウイルス組成物 |
| WO2022007800A1 (zh) * | 2020-07-06 | 2022-01-13 | 嘉兴安宇生物科技有限公司 | 一种非洲猪瘟的重组腺病毒疫苗及其构建方法 |
| CN116535491B (zh) * | 2022-05-06 | 2024-03-22 | 珠海丽凡达生物技术有限公司 | 治疗性核酸分子、混合物、药物及在治疗实体瘤中的应用 |
| WO2024015876A1 (en) | 2022-07-13 | 2024-01-18 | Epicentrx, Inc. | Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| AUPN477695A0 (en) | 1995-08-14 | 1995-09-07 | Commonwealth Scientific And Industrial Research Organisation | Gene therapy |
| GB9626029D0 (en) | 1996-12-14 | 1997-01-29 | Univ Leeds | EVH-1 vectors |
| US20040234505A1 (en) | 1998-09-23 | 2004-11-25 | Stuart Naylor | Polynucleotide constructs and uses thereof |
| CN1183250C (zh) | 2000-12-01 | 2005-01-05 | 卫健生物科技有限公司 | 高效表达肿瘤血管生成抑制因子的肿瘤细胞内特异性增殖的病毒及其构建方法 |
| US20040071659A1 (en) | 2001-04-30 | 2004-04-15 | Betty Chang | Viral-mediated delivery and in vivo expression of polynucleotides encoding anti-angiogenic proteins |
| CA2526120A1 (en) | 2003-06-03 | 2005-02-24 | Cell Genesys, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
| US20050136035A1 (en) | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
| US7473418B2 (en) | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
| CN101128593B (zh) | 2004-12-31 | 2014-09-03 | 佩尔·松内·霍尔姆 | 逆转动物细胞中多种抗性的方法 |
| KR100911624B1 (ko) * | 2007-05-14 | 2009-08-12 | 연세대학교 산학협력단 | Ｉｌ－１２ 및 ｉｌ－２３의 효율적인 공동발현 방법 |
| KR100896483B1 (ko) | 2007-07-13 | 2009-05-08 | 연세대학교 산학협력단 | Ｉｌ-12 및 4-1ｂｂｌ을 발현하는 종양 선택적 살상 재조합아데노바이러스 및 수지상 세포를 유효성분으로 포함하는항종양용 약제학적 조성물 |
| HUE046565T2 (hu) * | 2009-03-02 | 2020-03-30 | Univ California | Tumorszelektív adenovírus E1A és E1B mutánsok |
| US20130195800A1 (en) | 2010-03-23 | 2013-08-01 | Intrexon Corporation | Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof |
| KR101253276B1 (ko) | 2010-07-27 | 2013-04-10 | 윤채옥 | 복합 유전자 치료용 항종양 조성물 |
| BR112013006699A2 (pt) | 2010-09-24 | 2016-06-14 | Oncos Therapeutics Oy | vetor adenoviral oncolítico que codifica anticorpos anti-ctl4-4 monoclonais, célula e composição farmacêutica compreendendo o mesmo, método de produção de anticorpo monoclonal humano específico para ctla-4 em uma célula e uso do referido vetor adenoviral |
| US11155599B2 (en) | 2012-02-02 | 2021-10-26 | Board Of Regents, The University Of Texas System | Adenoviruses expressing heterologous tumor-associated antigens |
| DK3461491T3 (da) * | 2013-04-18 | 2025-02-03 | Tilt Biotherapeutics Oy | Forbedret adoptiv celleterapi |
| CN103614416B (zh) | 2013-09-30 | 2016-09-07 | 中国人民解放军第二军医大学东方肝胆外科医院 | 一种携带人穿膜肽p53与GM-CSF基因的重组溶瘤腺病毒及其用途 |
| KR102365331B1 (ko) | 2014-05-28 | 2022-02-22 | 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 | Reic 유전자를 발현하는 제한 증식형 아데노바이러스 |
| PL3198009T3 (pl) | 2014-09-24 | 2022-01-24 | Salk Institute For Biological Studies | Onkolityczne wirusy nowotworowe i sposoby zastosowania |
| WO2018083259A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| US10232053B2 (en) | 2016-12-30 | 2019-03-19 | Trieza Therapeutics, Inc. | Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer |
| US20190352616A1 (en) | 2017-01-30 | 2019-11-21 | Epicentrx, Inc. | Multiple transgene recombinant adenovirus |
| CA3064892A1 (en) | 2017-05-24 | 2018-11-29 | Epicentrx, Inc. | Anti-angiogenic adenovirus |
-
2017
- 2017-09-27 EA EA201990822A patent/EA201990822A1/ru unknown
-
2018
- 2018-04-12 WO PCT/US2018/027375 patent/WO2018191545A1/en not_active Ceased
- 2018-04-12 EP EP18784495.6A patent/EP3610025A4/en not_active Withdrawn
- 2018-04-12 CN CN201880038592.2A patent/CN110914440A/zh active Pending
- 2018-04-12 KR KR1020197033395A patent/KR20200006058A/ko active Pending
- 2018-04-12 US US16/604,675 patent/US12036247B2/en active Active
- 2018-04-12 JP JP2019555915A patent/JP7301748B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505049A5 (enExample) | ||
| JP2020521470A5 (enExample) | ||
| Xiao et al. | Trefoil factors: Gastrointestinal-specific proteins associated with gastric cancer | |
| Keller et al. | Mechanisms of impaired differentiation in rhabdomyosarcoma | |
| Weina et al. | SOX2 and cancer: current research and its implications in the clinic | |
| KR102164876B1 (ko) | ＩＬ12 및 ｓｈＶＥＧＦ 동시발현 아데노바이러스를 포함하는 항종양 면역성 증진 조성물 | |
| JP7438552B2 (ja) | 注射用医薬品、注射用調製物、および注射用医薬品の製造における使用 | |
| JP2014207903A5 (enExample) | ||
| Clemons et al. | Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction | |
| WO2008140621A3 (en) | Transgenic oncolytic viruses and uses thereof | |
| JP7301748B2 (ja) | 複数トランスジーン組み換えアデノウイルス | |
| CN110741080A (zh) | 多转基因重组腺病毒 | |
| EP1678193B1 (en) | Hepatocellular carcinoma specific promoter and uses thereof | |
| Krill et al. | Exploring the therapeutic rationale for angiogenesis blockade in cervical cancer | |
| CN105121635B (zh) | 突变型痘苗病毒株、其用途及其制造方法 | |
| Shen et al. | Specific CEA-producing colorectal carcinoma cell killing with recombinant adenoviral vector containing cytosine deaminase gene | |
| IL292788B2 (en) | Multivalent pd-l1 binding compounds for treating cancer | |
| CN103484462B (zh) | Survivin启动子调控CD基因的重组腺病毒载体构建及其应用 | |
| Lu et al. | Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses | |
| CN101671666B (zh) | 用于恶性肿瘤基因治疗的增殖和肿瘤细胞特异性基因操纵系统 | |
| Delgado‐Enciso et al. | A potent replicative delta‐24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms | |
| CN101497876B (zh) | 表达促凋亡基因的靶向增殖的重组腺病毒及其应用 | |
| Chengla et al. | Relationship between the expression of MTA-1 gene and the metastasis and invasion in human osteosarcoma | |
| EP2752429B1 (en) | Fusion protein comprising circularly permuted form of trail/apo2l, coding gene and use thereof | |
| Djalilvand et al. | Evaluation of p53 mutations in premalignant esophageal lesions and esophageal adenocarcinoma using laser capture microdissection |